Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial

The success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07).

Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine. 

Aclarion is a startup launched by UCSF based on the technologies developed by Dr. Jeffrey Lotz.